Can Coenzyme Q10 Supplements Ease the Side Effects of Paclitaxel Chemotherapy in Breast Cancer?

Table of Contents

• Key Points
• Why This Research Matters
• What the Researchers Wanted to Find Out
• Study Design: Who Participated and How the Trial Worked
• The Treatment Plan: Chemotherapy Plus CoQ10
• How Side Effects Were Measured
• Key Finding: Less Frequent and Later-Onset Nerve Damage
• Other Findings: Fatigue, Insomnia, Headache, Pain, and Digestive Symptoms
• Blood Counts and Heart Function
• What These Results Mean for Patients
• Study Limitations: What This Trial Could Not Prove
• Practical Recommendations: Questions for Your Doctor
• Frequently Asked Questions
• Source Information

Key Points

• In a 60-woman trial in Egypt, 400 mg daily of CoQ10 with weekly paclitaxel reduced moderate-to-severe peripheral neuropathy from 96% to 68% and delayed its onset by about 10 days.
• CoQ10 also lessened fatigue, insomnia, headache, mouth sores, diarrhea, and joint and muscle pain, and helped preserve hemoglobin and heart function over 12 weeks.
• The trial was open-label, small, and single-center, so results need confirmation in larger studies before CoQ10 becomes a standard recommendation.
• The study did not measure whether CoQ10 affected cancer response, recurrence, or survival; it only looked at side effects and tolerability.
• Patients interested in CoQ10 should discuss safety, dose, and interactions with their oncology team and never stop or reduce chemotherapy on their own.

Why This Research Matters

Breast cancer is the second most common cancer in the world and the second leading cause of cancer-related death, according to GLOBOCAN 2022 data from the International Agency for Research on Cancer (IARC), part of the World Health Organization (WHO). In Egypt, it is the most common cancer among women and the second leading cause of cancer death after liver cancer.

Many patients with early or locally advanced breast cancer receive a chemotherapy combination called anthracycline-taxane. Paclitaxel (often given under the brand name Taxol) is a key part of this regimen. It works well against cancer cells, but it can be hard to tolerate. Studies show that up to 87% of patients experience chemotherapy-related side effects during or after treatment.

The most important and feared side effect is peripheral neuropathy — nerve damage that causes tingling, numbness, burning, or pain in the hands and feet. Depending on the study, this affects anywhere from 11% to 87% of patients. It is followed in frequency by fatigue (affecting 11% to 71.5% of patients) and muscle and joint pain (up to 58%). All of these symptoms can seriously reduce quality of life.

Other common paclitaxel side effects include:

• Gastrointestinal problems: nausea, vomiting, and diarrhea
• Hematologic toxicity: low red blood cells (anemia) and low infection-fighting white blood cells (neutropenia)
• Skin and hair changes: hair loss (alopecia) and nail changes such as ridging or discoloration
• Mouth sores (oral mucositis)
• Sleep problems (insomnia) and headaches

Despite years of research, no medication has been firmly established to prevent these multiple chemotherapy side effects. Several drugs, including gabapentin, metformin, duloxetine, and various antioxidants, have been tested against paclitaxel-induced peripheral neuropathy (PIPN). None of them are currently recommended by the American Society of Clinical Oncology (ASCO). Fatigue is mostly managed with exercise and cognitive behavioral therapy. Glutamine has been tested for joint and muscle pain, with conflicting results. Even vitamin E, zinc, propolis, curcumin, and silymarin have shown inconclusive benefits.

One study by Serageldin and colleagues found that metformin reduced neuropathy, mouth sores, fatigue, and heart toxicity during AC-T therapy (a regimen combining doxorubicin, cyclophosphamide, and paclitaxel). But overall, the medical community still lacks a safe, broad-spectrum supportive agent that can protect patients from many chemotherapy side effects at once.

What the Researchers Wanted to Find Out

Coenzyme Q10 (CoQ10) is a natural substance your body produces. It is essential for energy production inside the mitochondria — the power plants of your cells — and it acts as a key defense against oxidative stress (cell damage caused by unstable molecules called free radicals). Organs that use a lot of energy, such as the heart, liver, skeletal muscles, and kidneys, depend heavily on CoQ10.

There were already hints that CoQ10 might help cancer patients. Clinical evidence suggested that CoQ10 supplementation could reduce anthracycline-related heart toxicity, which allowed patients to receive higher, more effective chemotherapy doses. CoQ10 also improved antioxidant capacity and reduced oxidative stress in patients treated for hepatocellular carcinoma (liver cancer). Animal studies in rats showed that CoQ10 protected against kidney damage from doxorubicin and gentamicin, and against paclitaxel-induced peripheral neuropathy.

Based on these promising findings, the study team set out to answer one main question: can CoQ10 supplementation reduce the side effects of paclitaxel chemotherapy in women with breast cancer — and make treatment easier to tolerate overall?

Study Design: Who Participated and How the Trial Worked

This was a parallel-group, open-label randomized controlled trial. "Randomized" means patients were assigned to one of two groups by chance, like flipping a coin. "Open-label" means both the patients and the doctors knew which group each patient was in.

The trial took place at Damanhour Oncology Center in Egypt. Ethical approval came from the Research Ethics Committee of the Faculty of Pharmacy at Damanhour University (IRB No. 823PP66). The trial was registered on ClinicalTrials.gov on August 26, 2024, under the identifier NCT06570811, before the first patient was enrolled. All patients gave written informed consent.

To be eligible, patients had to be women aged 18 years or older with newly diagnosed breast cancer and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 — meaning they were fully active or able to carry out light work. Patients were excluded if they were pregnant or breastfeeding, or if they had hereditary muscle disorders, diabetes mellitus, alcoholism, thyroid dysfunction, metastatic (spread) disease, advanced liver disease, chronic kidney disease, or a known allergy to CoQ10 or related compounds.

Between October 2024 and March 2025, 110 patients were assessed for eligibility. Fifty were excluded before randomization:

• Refused to participate: 13 patients
• Changes to their chemotherapy regimen: 15 patients
• Diabetes mellitus: 10 patients
• Metastatic disease: 12 patients

The remaining 60 patients were randomized in a 1:1 ratio: 30 patients received paclitaxel alone (the control group), and 30 patients received paclitaxel plus CoQ10 (the CoQ10 group).

Nine patients did not complete the study. In the CoQ10 group, 5 patients dropped out: 2 were lost to follow-up, 1 withdrew consent, 1 had poor adherence to the supplement, and 1 developed gastrointestinal intolerance to CoQ10. In the control group, 4 patients dropped out: 2 were lost to follow-up, and 2 switched to another chemotherapy protocol. In the end, 25 patients in the CoQ10 group and 26 in the control group completed the full 12 weeks and were included in the per-protocol analysis.

At the start, the two groups were comparable. The average age was about 51 years in both groups (51.12 ± 10.047 years in the control group versus 50.56 ± 12.376 years in the CoQ10 group, p = 0.861). Body mass index (BMI), menopausal status, cancer stage, and other characteristics were also similar between groups.

The Treatment Plan: Chemotherapy Plus CoQ10

All patients first completed four cycles of a standard chemotherapy protocol called AC, consisting of doxorubicin at 60 mg/m² plus cyclophosphamide at 600 mg/m². After that, patients who were still eligible were randomly assigned to one of two groups.

Both groups received the same chemotherapy: paclitaxel at 80 mg/m² given intravenously once a week for 12 weeks. This corresponds to four 3-week treatment cycles.

The CoQ10 group also took the supplement by mouth. The product used was Dozova CoQ10 Ubiquinol® (manufactured by Zeta Pharma, Egypt), supplied as hard gelatin capsules containing 200 mg of ubiquinol — the active, easily absorbed form of CoQ10. Patients took 200 mg twice daily, for a total daily dose of 400 mg, with breakfast and dinner to maximize absorption.

To keep the assignment process fair, the researchers used a computer-generated random sequence. Allocation was concealed using sequentially numbered, opaque, sealed envelopes that were opened only after a patient had completed her baseline assessment and signed consent. This step prevents the next treatment assignment from being predicted in advance.

Adherence to the supplement was checked at each chemotherapy cycle using two methods: pill counts from returned bottles and a daily dosing diary kept by each patient. Patients were considered "adherent" if they had taken at least 90% of the prescribed CoQ10 doses across the full 12 weeks.

How Side Effects Were Measured

All side effects were graded using the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0 — a standard scale used worldwide in cancer research. Grades run from 1 (mild) to 5 (death related to the side effect).

The primary outcome — the main question the study was designed to answer — was the cumulative incidence of grade ≥ 2 (moderate to severe) paclitaxel-induced peripheral neuropathy at week 12. This means the researchers counted how many patients in each group developed neuropathy severe enough to be clinically significant at any point during the 12 weeks of paclitaxel treatment.

The secondary outcomes included:

• Time-to-onset of grade ≥ 2 neuropathy (how many days into treatment before serious nerve symptoms appeared)
• Non-hematologic toxicities: fatigue, headache, insomnia, joint pain (arthralgia), muscle pain (myalgia), hair loss, nail changes, and gastrointestinal events including nausea, vomiting, diarrhea, constipation, and mouth sores
• Hematologic parameters: hemoglobin level, absolute neutrophil count (ANC, a measure of infection-fighting white blood cells), and platelet count
• Heart function: left ventricular ejection fraction (LVEF, the percentage of blood your heart's left chamber pumps out with each beat), measured by transthoracic echocardiography (an ultrasound of the heart)

It is worth noting that pathologic complete response (pCR) — meaning no cancer cells found after treatment — was not a study endpoint. This trial focused purely on side effects and tolerability, not on whether CoQ10 changed how well the chemotherapy worked against the cancer.

Side effects were tracked closely. Neuropathy and all other adverse events were assessed weekly throughout the 12 weeks. To avoid missing symptoms, the researchers used two reporting methods: structured face-to-face interviews with a trained physician before each chemotherapy session, plus structured telephone follow-ups three days after each session to capture new or temporary symptoms. Blood tests were done before each 3-week cycle. Hair loss and nail changes were checked at baseline and at week 12. Heart function was measured at baseline and again after the 12-week treatment period.

The researchers also actively asked CoQ10-group patients about possible supplement-related side effects, such as stomach discomfort, nausea, vomiting, diarrhea, dizziness, light sensitivity (photophobia), irritability, headache, or insomnia.

Key Finding: Less Frequent and Later-Onset Nerve Damage

The central result is clear: CoQ10 meaningfully reduced the risk of serious nerve damage. Grade ≥ 2 peripheral neuropathy occurred in 68% of the CoQ10 group versus 96% of the control group (p = 0.01). In plain terms, about 68 out of 100 patients taking CoQ10 developed significant neuropathy, compared with about 96 out of 100 patients not taking it — a 28-percentage-point absolute reduction. This result is statistically significant, meaning there is roughly a 1% chance it happened by random luck.

CoQ10 also delayed the onset of neuropathy. The median time to developing grade ≥ 2 neuropathy was 30.0 days (95% CI: 18.6–41.4) in the CoQ10 group versus 20.0 days (95% CI: 16.3–23.7) in the control group (log-rank p = 0.005). That is a 50% longer symptom-free window — about 10 extra days before serious nerve symptoms began.

In the per-protocol analysis, every single patient in the control group who completed the study (26 of 26) developed grade ≥ 2 neuropathy. In the CoQ10 group, 17 of 25 patients developed it, and 8 patients never reached that level of nerve damage.

The gap widened as treatment went on. Looking at weeks 10, 11, and 12 individually, the percentage of patients with grade 2–3 neuropathy in the control group was 76.9%, 92.3%, and 80.8%, respectively. In the CoQ10 group, the numbers were 68.0%, 64.0%, and 28.0%. By week 12, fewer than one in three CoQ10 patients had severe-grade neuropathy, versus more than four in five control patients. These differences remained statistically significant even after correction for multiple comparisons using the false discovery rate (FDR) method, with adjusted p-values of 0.05, 0.04, and 0.02 for weeks 10, 11, and 12.

Other Findings: Fatigue, Insomnia, Headache, Pain, and Digestive Symptoms

CoQ10 provided broader relief than just nerve protection. The most common adverse events in the whole study were mouth sores, nausea, anemia, headache, insomnia, diarrhea, fatigue, and peripheral neuropathy. Compared with the control group, CoQ10 patients showed lower severity for several symptom-based side effects, especially in the later weeks of treatment.

Insomnia differences appeared from week 9 and grew larger over time. By week 12, 76.9% of control patients reported grade 2–3 insomnia, compared with only 12% of CoQ10 patients (p < 0.001). That means about 77 out of 100 patients without CoQ10 had significant sleep problems at the end of treatment, versus about 12 out of 100 with CoQ10. This result was highly significant — less than a 0.1% chance of being random.

Fatigue was also less severe in the CoQ10 group from week 9 onward, and headache severity was lower starting from week 10, continuing through the rest of treatment.

Mouth sores (mucositis), diarrhea, joint pain (arthralgia), and muscle pain (myalgia) all showed significantly lower severity in the CoQ10 group from week 11 onward (p < 0.05).

Not everything improved, however. There were no significant differences between the groups for nausea, vomiting, constipation, dry mouth, urinary tract pain, febrile neutropenia (fever with dangerously low white blood cell counts), or thrombocytopenia (low blood platelets).

Blood Counts and Heart Function

CoQ10 also appeared to protect two systems that paclitaxel and related chemotherapy drugs can damage.

First, the blood. Hemoglobin — the oxygen-carrying protein inside red blood cells — stayed higher in the CoQ10 group by the end of treatment. At week 12, the difference was statistically significant (p = 0.009). In patient terms, CoQ10 patients were less likely to become anemic during their final weeks of paclitaxel therapy.

Second, the heart. The researchers measured left ventricular ejection fraction (LVEF) at the start and after 12 weeks. CoQ10 was associated with preservation of LVEF compared with the control group (p = 0.005). Since this trial's patients had all previously received doxorubicin — an "anthracycline" chemotherapy known to stress the heart — this finding is particularly relevant. It suggests CoQ10 may help shield the heart from the cumulative effects of chemotherapy.

What These Results Mean for Patients

Peripheral neuropathy is often the side effect that forces doctors to reduce, delay, or stop paclitaxel treatment. A safe supplement that lowers the chance of serious neuropathy from about 96% to 68%, and delays it by 10 days, could help more patients complete their planned chemotherapy at full dose. That matters, because completing the full course of chemotherapy is linked to better cancer outcomes.

The trial also points to CoQ10 as a possible "broad-spectrum" supportive agent — one that addresses several side effects at once rather than treating each symptom separately. A single supplement that eases nerve pain, fatigue, insomnia, mouth sores, diarrhea, and joint pain, while protecting blood counts and heart function, would fill a genuine gap in cancer care. Today, no such agent is firmly established.

The side effect profile of CoQ10 itself appeared acceptable. Most patients tolerated 400 mg daily without problems. The researchers actively monitored for supplement-related side effects, and only one patient in the CoQ10 group stopped because of gastrointestinal intolerance.

Study Limitations: What This Trial Could Not Prove

This study has important limitations that patients should understand before drawing conclusions.

• Open-label design: Both patients and doctors knew who was taking CoQ10. This can introduce bias, especially when measuring subjective symptoms like pain, fatigue, or insomnia. A double-blind design — where neither side knows the assignment — would provide stronger evidence.
• Small sample size: Only 60 patients were randomized, and 51 completed the study. Small trials can overestimate treatment effects.
• Single center: All patients were treated at one oncology center in Egypt, which may limit how well the results apply to other populations and healthcare settings.
• No cancer outcome data: The study did not measure whether CoQ10 affected pathologic complete response (pCR), recurrence, or survival. It only looked at side effects. Patients should not assume that CoQ10 improves or worsens how well chemotherapy fights cancer.
• No long-term follow-up: Side effects were tracked only during the 12 weeks of active treatment. The researchers did not assess whether CoQ10 affected neuropathy that persists or develops months after chemotherapy ends — a common and important problem for breast cancer survivors.
• Sample size assumptions: The study was designed assuming neuropathy would drop from 60% to 20% with CoQ10. The actual control rate was much higher (96%), which highlights how variable neuropathy reporting can be across studies and centers.

Practical Recommendations: Questions for Your Doctor

This single trial is not enough to make CoQ10 a routine recommendation for everyone receiving paclitaxel. But the results are promising enough that patients may reasonably discuss them with their oncology team. If you are about to start paclitaxel-based chemotherapy, consider asking your doctor:

1. Would CoQ10 be safe for me, given my specific medical history and current medications?
2. What dose would be appropriate? (In this study, patients took 200 mg of the ubiquinol form twice daily, with breakfast and dinner.)
3. Could CoQ10 interact with my chemotherapy or other drugs I take?
4. What should I watch for in terms of neuropathy, and how quickly should I report tingling or pain in my hands or feet?

If you and your doctor decide to try CoQ10, do not stop or reduce your chemotherapy on your own based on this study. The supplement was tested as an addition to standard treatment, not as a replacement. And remember that the product used in the trial was a specific ubiquinol formulation; other CoQ10 products may differ in absorption and quality.

Above all, keep reporting your symptoms. Whether or not you take CoQ10, early recognition of neuropathy, fatigue, and other side effects gives your care team the best chance to adjust your treatment and protect your quality of life.

Frequently Asked Questions

What did this trial find about CoQ10 and nerve damage from paclitaxel?

In a 60-woman trial in Egypt, those taking 400 mg of CoQ10 daily with weekly paclitaxel developed moderate-to-severe peripheral neuropathy less often: 68% versus 96% in the control group. Neuropathy also appeared about 10 days later on average. The trial was small and open-label, so larger studies are needed before CoQ10 becomes standard.

Who was eligible to join this CoQ10 and paclitaxel trial?

Eligible patients were women aged 18 or older with newly diagnosed breast cancer and an ECOG status of 0 to 2, meaning fully active or able to do light work. They were excluded if pregnant or breastfeeding, or if they had diabetes, metastatic disease, advanced liver or chronic kidney disease, thyroid dysfunction, alcoholism, hereditary muscle disorders, or a CoQ10 allergy.

What does it mean that 68% versus 96% developed serious neuropathy?

It means that out of 100 patients taking CoQ10, about 68 developed moderate-to-severe nerve damage, compared with about 96 out of 100 not taking it. That is a 28-percentage-point absolute reduction. The result was statistically significant, with roughly a 1% chance it happened by random luck, but it comes from one small trial.

How much CoQ10 did patients take and in what form?

Patients in the CoQ10 group took 200 mg of ubiquinol, the active easily absorbed form of CoQ10, twice daily for a total of 400 mg per day. They took it with breakfast and dinner to maximize absorption. The product used was a specific ubiquinol capsule; other CoQ10 products may differ in absorption and quality.

Did CoQ10 help with side effects other than nerve damage?

Yes, in this trial CoQ10 was linked to lower severity of fatigue, insomnia, headache, mouth sores, diarrhea, and joint and muscle pain, especially in later weeks. It also helped preserve hemoglobin levels and heart function over the 12-week treatment. However, nausea, vomiting, constipation, dry mouth, urinary tract pain, febrile neutropenia, and low platelets did not improve significantly.

What are the limitations of this CoQ10 trial?

The trial was open-label, so patients and doctors knew who took CoQ10, which can bias subjective symptom reporting. It was small, with 60 patients randomized and 51 completing, and it took place at a single center in Egypt. It did not measure whether CoQ10 affected cancer response, recurrence, or survival, and it had no long-term follow-up.

Should I take CoQ10 during my paclitaxel chemotherapy?

This single trial is not enough to make CoQ10 a routine recommendation for everyone receiving paclitaxel. You may reasonably discuss it with your oncology team, asking whether it is safe given your medical history and medications, what dose is appropriate, and about possible interactions. Do not stop or reduce chemotherapy on your own based on this study.

Should I get a second opinion before taking Coenzyme Q10 with paclitaxel chemotherapy for breast cancer?

A second opinion is reasonable before adding CoQ10 to weekly paclitaxel. The evidence comes from one small, open-label trial of 60 women at a single center, where 400 mg daily reduced serious nerve damage from 96% to 68% and delayed it by about ten days, and eased fatigue, insomnia, mouth sores, diarrhea, and joint pain. It did not measure whether CoQ10 affects how well chemotherapy fights cancer. Discuss the dose, form, and interactions with your oncology team first. Diagnostic Detectives Network provides independent expert second opinions.

Source Information

Original Article Title: Coenzyme Q10 as an adjunctive strategy to reduce paclitaxel-induced toxicities in breast cancer: a randomized controlled trial.

License: CC BY (open access)

Authors: Hassoub G, El-Bassiouny NA, Abdelkader Y, Badawy AA, Kassem AB.

Journal: BMC Pharmacology and Toxicology (2026) 27:95. Published by BioMed Central (BMC).

DOI: https://doi.org/10.1186/s40360-026-01163-7

Trial Registration: ClinicalTrials.gov identifier NCT06570811, registered August 26, 2024.

Ethics Approval: Research Ethics Committee, Faculty of Pharmacy, Damanhour University (IRB No. 823PP66).

This patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and does not replace individualized medical advice from your oncology care team.